[Endocrine markers in benign breast diseases].
Estimations of estradiol, progesteron and other biochemical analyses support the hypothesis of a relative unopposed hyperestrogenism as cause of benign breast diseases. Additional factors are insufficient luteal phases combined with hyperprolactinemia or transient prolactin pulses. Progestagen treatment applied either topically or both orally and topically can correct the imbalance and perhaps prevent breast cancer.
D001940:Breast / Q000378:metabolism; D002478:Cells, Cultured; D004958:Estradiol / Q000097:blood*; D005260:Female; D005348:Fibrocystic Breast Disease / Q000097:blood*; D006801:Humans; D008597:Menstrual Cycle; D011374:Progesterone / Q000097:blood*; D011388:Prolactin / Q000097:blood; D011959:Receptors, Estradiol / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism
D011959:Receptors, Estradiol; D011980:Receptors, Progesterone; D011374:Progesterone; D004958:Estradiol; D011388:Prolactin
Endokrine Merkmale bei benignen Mammaerkrankungen.